Benefits
Blood sugar support — ICMR Phase 2 evidence
A trial conducted by the Indian Council of Medical Research (ICMR) tested P. marsupium decoction in newly-diagnosed non-insulin-dependent diabetes mellitus (NIDDM) patients, measuring blood glucose levels and glycosylated hemoglobin (HbA1c). Foundational evidence for P. marsupium's antidiabetic applications.
Pterostilbene — more bioavailable than resveratrol
Pterostilbene is structurally a di-methylated version of resveratrol but with better bioavailability, potency, and metabolic stability. The methylation increases lipid solubility and resistance to first-pass metabolism. Practical advantage over resveratrol which has poor oral bioavailability (<1% in some studies). Same molecular target class but better drug-like properties.
Antioxidant — exceeds resveratrol
Pterostilbene's antioxidant activity is well above resveratrol against lipid peroxidation. Stilbenes are documented for antioxidant activity and cardiovascular effects. The enhanced potency vs resveratrol distinguishes pterostilbene as a more bioactive supplement option in the stilbene category.
PPARα induction (cardiovascular and metabolic)
Pterostilbene shows the highest induction of PPAR-alpha among stilbenes. PPAR-alpha is a key transcription factor regulating fatty acid metabolism, lipid homeostasis, and cardiovascular health, the same mechanism class as fibrate drugs (fenofibrate). The PPAR-alpha effect supports the cholesterol-lowering applications.
Insulin sensitivity improvement
Pterostilbene improves insulin sensitivity and proper sugar level, with effects comparable to metformin per published research. The (-)-epicatechin component has documented insulin-like activity. Combined mechanisms address both insulin sensitivity (cells responding to insulin) and insulin secretion.
Antimicrobial — 5-10× more potent than resveratrol
Pterostilbene has antimicrobial activity 5-10× more potent than resveratrol per published research. Mechanism supports broader healthspan applications beyond metabolic effects. Antimicrobial activity contributes to traditional Ayurvedic use of Pterocarpus marsupium for digestive and infectious applications.
Anti-inflammatory (COX-2 inhibition)
Pterostilbene has documented anti-inflammatory effects via COX-2 inhibition, the same target class as NSAIDs. The mechanism supports applications in inflammatory metabolic disease (chronic low-grade inflammation drives metabolic syndrome). It also has analgesic effects.
TMAO reduction (cardiovascular)
Pterostilbene has been studied for trimethylamine N-oxide (TMAO) lowering. TMAO is an independent dose-dependent risk factor for atherosclerosis and CVD, and for colorectal cancer in postmenopausal women. Ingredients that lower TMAO are welcome additions to cardiovascular supplement portfolios.
Safety established — 200 mg/day clinical trial
A safety trial gave healthy adults Silbinol 90% pterostilbene 100 mg twice daily (200 mg/day) or placebo for 2 months. Hematological, lipid, glycemic, thyroid, liver, and renal function parameters remained within normal range, with no serious adverse events. Trial registration CTRI/2019/08/020736.
Mechanism of action
PPARα activation
Pterostilbene shows the highest PPARα induction among stilbenes. PPARα regulates fatty acid oxidation, lipid metabolism, and inflammatory response. Activated PPARα reduces triglycerides and LDL cholesterol — same mechanism as fibrate drugs (fenofibrate). The mechanism explains the cholesterol-lowering applications of Silbinol.
Insulin signaling enhancement
(-)-Epicatechin in Silbinol has documented insulin-like activity — directly supporting insulin signaling. Combined with pterostilbene's effects on insulin sensitivity, Silbinol addresses multiple aspects of glucose homeostasis. Comparative studies confirm similarity between (-)-epicatechin and insulin mechanisms.
COX-2 anti-inflammatory inhibition
Pterostilbene inhibits cyclooxygenase-2 (COX-2) — the inflammatory isoform of the enzyme producing prostaglandins. Same target as NSAIDs (with milder magnitude). Mechanism reduces inflammatory contribution to metabolic and cardiovascular disease.
Lipid peroxidation prevention
Pterostilbene's antioxidant activity exceeds resveratrol against lipid peroxidation. Lipid peroxidation drives atherosclerosis via oxidized LDL formation. Preventing lipid peroxidation supports cardiovascular health alongside the direct lipid-lowering effects.
Methylation-enhanced bioavailability
Pterostilbene's two methyl groups (vs resveratrol's hydroxyl groups) increase lipid solubility and resistance to phase II metabolism (glucuronidation, sulfation). Result: 80-95% oral bioavailability vs <1% for resveratrol. The bioavailability advantage explains why pterostilbene produces effects at lower doses than resveratrol.
Clinical trials
Randomized double-blind placebo-controlled study evaluating Silbinol® at 100 mg twice daily (200 mg/day) for 2 months in healthy adults. Primary outcomes: changes in laboratory parameters, vital signs, adverse events. Secondary: serum antioxidant enzyme levels. Published in peer-reviewed journal. CTRI/2019/08/020736.
60 healthy adult participants (27 males, 33 females). 2-month intervention with 100 mg Silbinol bid or placebo.
Hematological, lipid, glycemic, thyroid profiles, liver and renal functions remained within normal range — no differences between groups. No serious adverse events. Glutathione levels relatively higher in the PME group (antioxidant effect). Established safety of >90% pterostilbene at 200 mg/day for human use. Foundation for therapeutic applications.
Phase 2 open trial conducted by the Indian Council of Medical Research (ICMR) at 4 centers in India testing P. marsupium decoction for 12 weeks in newly-diagnosed non-insulin-dependent diabetes mellitus (NIDDM) patients. Foundational efficacy evidence. Published in Indian Journal of Medical Research.
93 newly-diagnosed NIDDM patients. 12-week intervention with P. marsupium decoction.
Documented improvements in blood glucose levels and glycosylated hemoglobin (HbA1c) with P. marsupium intervention. Foundational evidence supporting Silbinol's metabolic positioning. Traditional decoctions and modern standardized extracts provide consistent antidiabetic effects in NIDDM patients.
Class evidence for pterostilbene pharmacology across preclinical and clinical research. Studies include Rimando et al. (PPARα induction), Manickam et al. (insulin sensitivity), Remsberg et al. (analgesic), Satheesh and Pari (antidiabetic mechanism), and others.
Various — animal models and in vitro studies of pterostilbene pharmacology.
Pterostilbene consistently demonstrates: PPARα activation (highest among stilbenes), insulin sensitivity improvement comparable to metformin, anti-inflammatory effects via COX-2 inhibition, antioxidant activity exceeding resveratrol, antimicrobial activity 5-10× resveratrol, and UV protection. Multi-mechanism profile supports broad applications across metabolic, cardiovascular, and inflammatory health.